Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine for agitation in adults with bipolar disorder
IRCT20230630058623N1Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bipolar disorder (BD) comparing Dexmedetomidine with Placebo control (2 arms). Primary endpoints: Average agitation score before and after treatment, Patient satisfaction and 1 more. Started Jul 2023; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on IRCT20230630058623N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230630058623N1.